Abstract
Background:
Patients with chronic obstructive pulmonary disease (COPD) after acute coronary artery syndrome (ACS) are at an increased risk of heart failure and death. However, β-blockers have been underused in this population group due to concerns of adverse reactions.
Objective:
This study aims to investigate the β-blocker prescription at admission and its impact on the in-hospital outcomes in patients with COPD after ACS in a Chinese national cohort.
Methods:
Among 113,650 patients with ACS enrolled in the national registry of the Improving Care for Cardiovascular Disease in China between November 2014 and July 2019, a total of 1,084 ACS patients with COPD were included in this study. The primary endpoint was in-hospital mortality, and the secondary endpoint was the composite of in-hospital all-cause death and heart failure.
Results:
Early oral β-blocker therapy was administered to 49.8% of patients. The Kaplan–Meier analysis showed that the early β-blocker treatment group had lower all-cause mortality (0.9% vs. 2.9%; P < 0.05) and lower combined endpoint event rate (8.2% vs. 12.0%; P < 0.05) compared to the those of the non-early β-blocker treatment group. The analysis of inverse probability of treatment weighting showed that the early β-blocker treatment group was associated with a significantly reduced incidence of all-cause death (risk ratio, 0.332, 0.119–0.923, P = 0.035), heart failure (risk ratio, 0.625, 95% CI 0.414–0.943, P = 0.025), and combined endpoint events (risk ratio: 0.616, 95% CI: 0.418–0.908, P = 0.014). In the subgroup of patients over 70 years of age, the corresponding hazard ratio was 0.268 (95% CI 0.077–0.938) for all-cause mortality and 0.504 (95% CI 0.316–0.805) for combined endpoint events.
Conclusion:
β-blockers have been underused in patients with COPD and ACS in China. Early β-blocker therapy is associated with an improvement in in-hospital outcomes in patients with COPD after ACS.
Clinical Trial Registration:
ClinicalTrials.gov, identifier (NCT02306616).
1 Introduction
Patients with acute coronary syndrome (ACS) and chronic obstructive pulmonary disease (COPD) are a high-risk population. Compared to patients without COPD, patients with COPD after acute myocardial infarction (AMI) have a higher risk of heart failure (1) and mortality (2, 3). Hypoxia and systemic inflammation may be involved in the pathophysiological interactions between ACS and COPD (4). Thus, it is important to reduce adverse events after ACS in this population.
The inadequate use of revascularization and secondary prevention medications are potential reasons for the mortality gap in patients with COPD following AMI (2). β-blockers have been underused in patients with COPD and ACS due to concerns about their adverse effects on the respiratory function of patients with COPD (5). The clinical benefits of β-blockers after ACS have been proven by contemporary trials (6, 7). However, the evidence of early β-blocker use in COPD patients following ACS remains limited.
This study aims to explore the association between early β-blocker use (within 24 h of admission) and in-hospital outcomes in patients with COPD and ACS in a national registry and identify the factors influencing the use of β-blockers in patients with COPD.
2 Materials and methods
2.1 Participants
The Improving Care for Cardiovascular Disease in China-ACS Project (CCC-ACS), a collaborative effort by the American Heart Association and the Chinese Society of Cardiology, is an ongoing national quality improvement program launched in November 2014 and involves 150 tertiary hospitals in China. Since 2017, the CCC-ACS program has extended to 82 secondary hospitals and another 8 tertiary hospitals. Details of the study design were reported in a previous study (8). The CCC-ACS project was approved by the Institutional Review Committee of Beijing Anzhen Hospital, and informed consent was waived. This study was registered at ClinicalTrials.gov (NCT02306616) and is in accordance with the Helsinki Declaration. From November 2014 to July 2019, a total of 113,650 patients with ACS were enrolled in this study. We focused our analysis on participants with COPD.
2.2 Definitions of variables
The medical history and periprocedural details were obtained from the patients’ medical charts and entered into the database by trained data abstractors. Standardized definitions were utilized across all hospitals for variable collection. Since metoprolol and bisoprolol are the most commonly used β-blocker in Chinese patients with ACS, β-blocker users were defined as receiving these two kinds of β-blocker. Early oral β-blocker therapy was defined as the initiation of therapy within 24 h after admission. Non-early oral β-blocker therapies included oral β-blocker therapy initiated more than 24 h after admission or no β-blocker therapy administered during hospitalization. Patients who received early intravenous β-blocker were excluded from this analysis. The diagnoses of COPD were retrieved from the Improving Care for Cardiovascular Disease in China-ACS registry (CCC-ACS) using ICD-9 codes 491–492 and 496 and ICD-10 codes J41–J44, excluding cases coded for asthma. Myocardial infarction is defined as an increase of cardiac troponin with at least one value above the 99th percentile upper reference limit and ischemic symptoms and/or new or presumed new ST-segment, T-wave changes, or new left bundle branch block (9).
Patients meeting one of the following criteria were excluded: (1) cardiogenic shock or cardiac arrest at admission; (2) hemodynamic instability [systolic blood pressure (SBP) <85 mmHg or heart rate <50 beats/minute] at admission; (3) patients with acute heart failure at admission; (4) contraindications to β-blocker therapy, including second- or third-degree atrioventricular block and bradycardia; (5) mechanical complications (ventricular septal perforation, papillary muscle rupture, and myocardial rupture); (6) patients who received early intravenous β-blocker; and (7) length of hospital stay ≤1 day or >15 days.
2.3 Endpoints
The primary endpoint was in-hospital all-cause mortality. The secondary endpoint was combined endpoint events, including in-hospital all-cause death and heart failure.
2.4 Statistical analysis
Continuous variables with a normal distribution are presented as the means and standard deviations. Continuous variables with a skewed distribution are presented as the medians with 25th–75th percentiles. Differences in baseline characteristics were tested with the chi-square and t-test or Kruskal–Wallis tests for categorical and continuous variables, respectively. Kaplan–Meier methods were used to estimate the in-hospital event rates for each endpoint, and comparisons between the study groups were performed using the log-rank test.
To consolidate the findings, we also performed the inverse probability of treatment weighting (IPTW) using the propensity score method in the study cohort and compared the differences between the early β-blocker and non-early β-blocker treatment groups. Logistic regression was performed to estimate the propensity score (PS), getting the following variables adjusted: age, sex, current smoker, previous disease history [myocardial infarction (MI), percutaneous coronary intervention (PCI), diabetes, hypertension, ischemic stroke], Killip class, pre-hospital treatment in 2 weeks (β-blocker, ACEI/ARB, statin, aspirin), treatment within 24 h of admission (DAPT, P2Y12 inhibitor, aldosterone antagonist, ACEI/ARB, statin), and type of MI and PCI treatment. The IPTW was calculated by each individual based on his or her PS. Each case from the early β-blocker group was given a weight of Pt/PS, where Pt refers to the proportion of patients receiving early β-blocker among the whole cohort, and each case from the non-early β-blocker group was given a weight of (1-Pt)/(1-PS). In this way, we obtained a stabilized weight for each case of the study cohort, avoiding any extreme values that may result in unreliable outcomes.
All tests were two-sided with a P-value for significance of <0.05. All analyses were performed using SAS version 9.4 software (SAS Institute, Cary, NC, United States).
3 Result
3.1 Patient characteristics
As shown in Figure 1, a total of 1,084 patients with COPD were identified in the CCC-ACS project with the inclusion and exclusion criteria applied. Among them, 540 (49.8%) patients had early oral β-blocker treatment within 24 h after admission. The baseline characteristics of the study cohort are summarized in Table 1. Compared to the non-early β-blocker treatment group, the early β-blocker treatment group had a significantly higher prevalence of hypertension (73.3 vs. 67.1%, P = 0.025). Cardiovascular medications were more frequently used at admission in the early β-blocker treatment group, including aspirin, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, and statin (Table 2). After adjustment using the IPTW and propensity score-matched methods, the baseline characteristics were well-balanced (Supplementary Material Table S1).
Figure 1
Flowchart of the study. ACS, acute coronary syndrome; CCC-ACS, Care for Cardiovascular Disease in China-Acute Coronary Syndromes; COPD, chronic obstructive pulmonary disease.
Table 1
| Variables | Early use of β-blocker (n = 540) | Non-early use of β-blocker (n = 544) | P-value |
|---|---|---|---|
| Age, year, mean (SD) | 72.6 ± 9.2 | 73.0 ± 9.7 | 0.552 |
| Male, n (%) | 419 (77.6) | 416 (76.5) | 0.661 |
| BMI, kg/m2, mean (SD) | 23.5 ± 3.6 | 23.4 ± 4.1 | 0.867 |
| Current smoker, n (%) | 214 (39.6) | 226 (41.5) | 0.521 |
| HBP, n (%) | 396 (73.3) | 365 (67.1) | 0.025 |
| DM, n (%) | 191 (35.4) | 193 (35.5) | 0.970 |
| Dyslipidemia, n (%) | 59 (10.9) | 52 (9.6) | 0.458 |
| STEMI at presentation, n (%) | 248 (45.9) | 261 (48.0) | 0.499 |
| Prior comorbidity, n (%) | |||
| Heart failure | 44 (8.1) | 51 (9.4) | 0.475 |
| MI | 66 (12.2) | 50 (9.2) | 0.107 |
| Stroke | 77 (14.3) | 71 (13.1) | 0.563 |
| Peripheral arterial disease | 27 (5.0) | 23 (4.2) | 0.545 |
| Atrial fibrillation | 36 (6.7) | 30 (5.5) | 0.428 |
| History of myocardial revascularization, n (%) | |||
| PCI | 63 (11.7) | 49 (9.0) | 0.150 |
| CABG | 4 (0.7) | 2 (0.4) | 0.408 |
| Blood pressure, mean (SD), mmHg | |||
| SBP | 132.4 ± 21.7 | 132.2 ± 21.8 | 0.857 |
| DBP | 77.8 ± 13.6 | 76.5 ± 12.8 | 0.112 |
| Heart rate, beats/min, mean (SD) | 80.7 ± 14.8 | 79.7 ± 17.6 | 0.331 |
| Killip classesⅡ–Ⅲ, n (%) | 211 (39.1) | 258 (47.4) | 0.006 |
| eGFR, mean (SD), ml/min/1.73 m2 | 76.2 ± 21.2 | 75.3 ± 23.4 | 0.552 |
| Renal insufficiency, n (%) | 113 (20.9) | 132 (24.3) | 0.176 |
| Serum creatinine level, mean (SD), mg/dl | 1.0 ± 0.6 | 1.0 ± 0.5 | 0.788 |
| Hemoglobin, g/L, mean (SD) | 132.7 ± 20.4 | 131.1 ± 20.4 | 0.221 |
| LVEF, mean (SD), % | 55.4 ± 9.9 | 55.1 ± 9.9 | 0.651 |
Characteristics of patients with ACS and COPD according to β-blocker use.
BMI, body mass index; CABG, coronary artery bypass graft; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HBP, high blood pressure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NA, not applicable; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; SD, standard deviation; STEMI, ST-elevation myocardial infarction; UAP, unstable angina pectoris.
Table 2
| Medication | Early use of β-blocker (n = 540) | Non-early use of β-blocker (n = 544) | P-value |
|---|---|---|---|
| Medication within 24 h after admission, n (%) | |||
| Aspirin | 491 (90.9) | 441 (81.1) | <0.001 |
| P2Y12 inhibitora | 414 (76.7) | 392 (72.1) | 0.082 |
| Aldosterone antagonist | 118 (21.9) | 109 (20.0) | 0.463 |
| ACEI/ARB | 331 (61.3) | 177 (32.5) | <0.001 |
| Statin | 517 (95.7) | 496 (91.2) | 0.002 |
| Procedure | |||
| PCI (%) | 306 (56.7) | 287 (52.8) | 0.196 |
| CABG (%) | 3 (0.6) | 5 (0.9) | 0.484 |
Medication and procedure in patients with ACS and COPD according to β-blocker use.
ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
P2Y12 inhibitor, including clopidogrel and prasugrel.
3.2 Association between early β-blocker therapy and in-hospital outcomes
The Kaplan–Meier survival analysis showed that the incidence of the all-cause death (0.9 vs. 2.9%, P < 0.05, Figure 2A) and combined endpoint event (8.2 vs. 12.0%, P < 0.05, Figure 2C) were significantly lower in the early β-blocker treatment group compared to the non-early β-blocker treatment group.
Figure 2
In-hospital clinical outcomes (unadjusted analysis). Early β-blocker treatment group (blue line) vs. non-early β-blocker treatment group (red line).
The association between early β-blocker therapy and the risk of in-hospital outcomes was analyzed using IPTW-weighted Cox regression analysis. After the IPTW, the absolute standard deviations of the baseline characteristics of the patients in the two groups were all <10%. The characteristics of the two groups after IPTW are shown in Supplementary Material Table S1. The post-IPTW results indicated that the early β-blocker treatment group had a significantly lower risk of in-hospital all-cause mortality (OR = 0.332, 95% CI: 0.119–0.923, P = 0.035), heart failure (OR = 0.625, 95% CI: 0.414–0.943, P = 0.025), and combined endpoint event (OR = 0.616, 95% CI: 0.418–0.908, P = 0.014) than those of the non-early β-blocker treatment group (Table 3).
Table 3
| Study group | P-value | Unadjusted | After IPTW | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Early use of β-blocker (n = 540) | Non-early use of β-blocker (n = 544) | OR | 95% CI | P-value | OR | 95%CI | P-value | ||
| All-cause death | 5 (0.9) | 16 (2.9) | 0.016 | 0.307 | 0.112–0.838 | 0.021 | 0.332 | 0.119–0.923 | 0.035 |
| Heart failure | 40 (7.4) | 57 (10.5) | 0.077 | 0.695 | 0.464–1.041 | 0.077 | 0.625 | 0.414–0.943 | 0.025 |
| Combined endpoint | 44 (8.2) | 65 (12.0) | 0.038 | 0.668 | 0.456–0.980 | 0.039 | 0.616 | 0.418–0.908 | 0.014 |
Associations between early oral β-blocker therapy and in-hospital outcomes.
Logistic regression was performed to estimate the propensity score, adjusting for the following variables: age, sex, current smoker, previous disease history (MI, PCI, ischemic stroke), diabetes mellitus, hypertension, Killip class, type of ACS, PCI, pre-hospital medication (β-blocker, statin, ACEI/ARB, aspirin), and medication within 24 h after admission (DAPT, P2Y12 inhibitor, aldosterone antagonist, ACEI/ARB, statin). IPTW was calculated by each individual based on his or her propensity score (PS).
3.3 Subgroup analysis
Subgroup analyses are shown in Figure 3. Patients older than 70 years with COPD after ACS had a hazard ratio of 0.268 (95% CI 0.077–0.938) for in-hospital all-cause mortality, while those aged 70 years or less had a hazard ratio of 0.586 (95% CI 0.094–3.654) (Figure 3A), suggesting that older patients may benefit more from early β-blocker use. Patients with non-ST-segment elevated ACS had a hazard ratio of 0.073 (95% CI 0.004–1.223) for in-hospital all-cause mortality, while those presented as ST-segment elevated ACS had a hazard ratio of 0.579 (95% CI 0.179–1.872).
Figure 3
Subgroup analysis (adjusted with IPTW). Hazard ratio and confidence intervals for all-cause death (A) and combined endpoint (B) in the early β-blocker treatment group compared to the non-early β-blocker treatment group. IPTW, inverse probability of treatment weighting.
The hazard ratio for the combined endpoint events was 0.504 (95% CI 0.316–0.805) in patients older than 70 years (Figure 3B). Patients aged 70 years or younger had a hazard ratio of 0.988 (95% CI 0.482–2.026). Patients with non-ST-segment elevated ACS had a hazard ratio of 0.451 (95% CI 0.249–0.817) for combined endpoint events, indicating that patients with non-ST-segment elevated ACS may also benefit from early β-blocker use. Patients with ST-segment elevated ACS had a hazard ratio of 0.801 (95% CI 0.477–1.346).
4 Discussion
β-Blocker therapy was underused in Chinese patients with COPD after ACS. Early oral β-blocker therapy was administered to only 49.8% of patients at admission in this specific population cohort. We found that early oral β-blocker therapy was independently associated with a lower incidence of in-hospital outcomes (heart failure and all-cause death) in patients with ACS and COPD. Our results suggested that patients with COPD after ACS initiated with early oral β-blocker treatment had a lower incidence of in-hospital heart failure and all-cause death compared to those who were not prescribed with β-blockers.
The underuse of the β-blockers in patients with COPD after ACS is a worldwide phenomenon. Our findings in China are consistent with those of the previous studies in other countries (10–13). However, the frequency of β-blocker prescriptions in the present study was much lower than that reported in studies from Western countries. For example, a Swedish nationwide study reported an 84.1% β-blocker prescription rate at discharged COPD patients after MI (13). A study based in the US indicated a marked increase in the use of β-blockers from 64% in 1997 to 93% in 2007 in patients with COPD who developed AMI (11). Meanwhile, another study from the US found β-blocker prescription rates of 65.6% at admission and 77.2% at discharge in ACS patients with a reactive airway disease history (12). Compared with the practices in Western countries, β-blockers in COPD patients following ACS are underused in China. Our study showed that less than one-half of the patients with ACS and COPD were prescribed with β-blocker upon admission. The present study also found that the group using β-blocker had a higher prevalence of hypertension. At the same time, this group was more often prescribed aspirin, ACEI/ARB, and statin. Overall, patients with COPD and ACS who simultaneously had hypertension were more likely to take β-blockers. This might be because β-blockers are commonly used for patients with hypertension in China.
We found that early use of β-blockers after ACS was associated with better in-hospital outcomes, benefiting from a reduction in the incidence of death and heart failure. This correlation was more pronounced in elder patients. Heart failure is common in patients with AMI and is the strongest predictor of death (14). A previous study indicated that respiratory disease was independently related to ischemia heart disease and heart failure (15). COPD was found to be an independent predictor of heart failure in patients with AMI (16). There is evidence that β-blockers do not adversely affect the lung function of patients with COPD (17, 18). Thus, we should be more determined and certain in prescribing β-blockers in COPD patients following ACS as this population could benefit more from β-blocker use.
Several limitations should be acknowledged. This is a multicenter, observational retrospective analysis; therefore, there might be a certain degree of residual confounding owing to the nature of the study. Furthermore, a wide range of physicians were involved in diagnosing COPD patients; thus, the diagnostic criteria might be heterogeneous. The CCC program collected information on whether patients received oral β-blocker therapy within 24 h of admission, but did not record the duration and daily dose of β-blocker use during the hospitalization. Hence, we were unable to further analyze the relationship between the dose-dependent effect of β-blockers and in-hospital outcomes. The effects of different treatment patterns of early β-blocker usage on in-hospital outcomes could be further evaluated in future studies if the daily β-blocker dosage data during hospitalization were available.
5 Conclusion
β-Blockers are underused in Chinese patients with COPD after ACS. The early use of β-blockers in patients with COPD after ACS, which is defined as β-blocker administration within 24 h post-admission, was associated with a lower incidence of in-hospital all-cause death and heart failure when compared to non-early use of a β-blocker. The results suggest that patients with ACS and COPD may benefit from the early use of β-blockers.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Author contributions
TZ: Writing – original draft. XW: Writing – review & editing. YZ: Formal Analysis, Investigation, Writing – review & editing. TF: Data curation, Writing – review & editing. YZ: Supervision, Writing – review & editing. LZ: Writing – original draft, Writing – review & editing.
Funding
The authors declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
We deeply thank the staff members of the Department of Epidemiology at Beijing Anzhen Hospital for their contributions. We also thank all the staff members of the Department of Cardiology and the Department of Emergency Critical Care Center at the Beijing Anzhen Hospital for their efforts in this work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2024.1385943/full#supplementary-material
References
1.
Hawkins NM Huang Z Pieper KS Solomon SD Kober L Velazquez EJ et al Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. (2009) 11:292–8. 10.1093/eurjhf/hfp001
2.
Rothnie KJ Smeeth L Herrett E Pearce N Hemingway H Wedzicha J et al Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. (2015) 101:1103–10. 10.1136/heartjnl-2014-307251
3.
Salisbury AC Reid KJ Spertus JA . Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. (2007) 99:636–41. 10.1016/j.amjcard.2006.09.112
4.
Goedemans L Bax JJ Delgado V . COPD and acute myocardial infarction. Eur Respir Rev. (2020) 29(156):190139. 10.1183/16000617.0139-2019
5.
Parkin L Quon J Sharples K Barson D Dummer J . Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: a nationwide follow-up study in New Zealand. Respirology. (2020) 25:173–82. 10.1111/resp.13662
6.
Aarvik M D Sandven I Dondo TB Gale CP Ruddox V Munkhaugen J et al Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. (2019) 5:12–20. 10.1093/ehjcvp/pvy034
7.
Martínez-Milla J Raposeiras-Roubín S Pascual-Figal DA Ibáñez B . Role of beta-blockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed). (2019) 72:844–52. 10.1016/j.rec.2019.04.014
8.
Hao Y Liu J Liu J Smith SC Jr. Huo Y Fonarow GC et al Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: a national effort to prompt quality enhancement for acute coronary syndrome. Am Heart J. (2016) 179:107–15. 10.1016/j.ahj.2016.06.005
9.
Thygesen K Alpert JS Jaffe AS Chaitman BR Bax JJ Morrow DA et al Fourth universal definition of myocardial infarction (2018). Circulation. (2018) 138:e618–51. 10.1161/CIR.0000000000000617
10.
Bursi F Vassallo R Weston SA Killian JM Roger VL . Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J. (2010) 160:95–101. 10.1016/j.ahj.2010.05.004
11.
Stefan MS Bannuru RR Lessard D Gore JM Lindenauer PK Goldberg RJ . The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study. Chest. (2012) 141:1441–8. 10.1378/chest.11-2032
12.
Olenchock BA Fonarow GG Pan W Hernandez A Cannon CP . Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol. (2009) 103:295–300. 10.1016/j.amjcard.2008.09.081
13.
Andell P Erlinge D Smith JG Sundström J Lindahl B James S et al β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. (2015) 4(4):e001611. 10.1161/JAHA.114.001611
14.
Granger CB Goldberg RJ Dabbous O Pieper KS Eagle KA Cannon CP et al Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. (2003) 163:2345–53. 10.1001/archinte.163.19.2345
15.
Carter P Lagan J Fortune C Bhatt DL Vestbo J Niven R et al Association of cardiovascular disease with respiratory disease. J Am Coll Cardiol. (2019) 73:2166–77. 10.1016/j.jacc.2018.11.063
16.
Enriquez JR Parikh SV Selzer F Jacobs AK Marroquin O Mulukutla S et al Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. (2011) 140:604–10. 10.1378/chest.10-2644
17.
Short PM Lipworth SI Elder DH Schembri S Lipworth BJ . Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. Br Med J. (2011) 342:d2549. 10.1136/bmj.d2549
18.
Dransfield MT Rowe SM Johnson JE Bailey WC Gerald LB . Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. (2008) 63:301–5. 10.1136/thx.2007.081893
Summary
Keywords
β-blocker, chronic obstructive pulmonary disease, acute coronary artery syndrome, in-hospital outcomes, early use
Citation
Zhang T, Wang X, Zhang Y, Feng T, Zhou Y and Zhao L (2024) Early β-blocker use and in-hospital outcomes in patients with chronic obstructive pulmonary disease hospitalized with acute coronary syndrome: findings from the CCC-ACS project. Front. Cardiovasc. Med. 11:1385943. doi: 10.3389/fcvm.2024.1385943
Received
14 February 2024
Accepted
24 June 2024
Published
11 July 2024
Volume
11 - 2024
Edited by
Verena Veulemans, University Heart and Vascular Center Frankfurt, Germany
Reviewed by
Małgorzata Ostrowska, Nicolaus Copernicus University in Toruń, Poland
Sawan Jalnapurkar, Gadsden Regional Medical Center, United States
Updates
Copyright
© 2024 Zhang, Wang, Zhang, Feng, Zhou and Zhao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lin Zhao trichina2007@126.com
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.